Gufic Biosciences FY26 results, margin outlook and capex plans
Gufic Biosciences reported Q4FY26 revenue of INR252 crore and PAT of INR20.5 crore. Management targets 15% revenue growth and EBITDA margins exceeding 20% by 2030.
*this image is generated using AI for illustrative purposes only.
Gufic Biosciences has reported its financial results for the fourth quarter and financial year ended March 31, 2026. The company recorded its strongest quarterly revenue of INR252 crore in Q4FY26, a jump of over 15% from INR205 crore in the previous year. Profit after tax (PAT) for the quarter more than doubled to INR20.5 crore from INR8 crore in Q4FY25. For the full year FY26, revenue stood at INR940.50 crore, while PAT was INR63.2 crore. The management attributed the performance to a strong Q4, operational improvements, and strategic shifts in the business model.
Financial Performance
The company's EBITDA for Q4FY26 rose to INR44.7 crore, up from INR27 crore in the corresponding period of the previous year, with the EBITDA margin expanding to 17.73% from 13.17%. For the full year FY26, EBITDA was INR152.9 crore on a revenue of INR940.50 crore. The table below summarises the key financial metrics for the quarter and the full year:
| Metric | Q4FY26 | Q4FY25 | FY26 | FY25 |
|---|---|---|---|---|
| Revenue (INR crore) | 252 | 205 | 940.50 | 820 |
| EBITDA (INR crore) | 44.7 | 27 | 152.9 | 138.6 |
| EBITDA Margin (%) | 17.73 | 13.17 | 16.26 | 16.91 |
| PAT (INR crore) | 20.5 | 8 | 63.2 | 69.9 |
Management Guidance
During the earnings conference call, management provided guidance for the coming years. The company targets a revenue growth of 15% year-over-year. On the profitability front, the EBITDA margin for FY27 is expected to be around 18%, with an annual improvement of 0.50% to 1% anticipated thereafter. By 2030, the company aims to achieve EBITDA margins exceeding 20%.
Gross margins are also projected to improve by 0.50% to 1% annually, driven by product mix optimisation, geography mix, and pricing strategies. The company expects gross debt to remain around INR400 crore to support working capital requirements for top-line growth.
Capital Expenditure and Operational Updates
The management stated that no greenfield capital expenditure is foreseen for the next two years. However, replacement CapEx of approximately INR20 crore annually is planned to ensure business continuity. The Indore facility, which reached 30% capacity utilisation in Q4FY26, has achieved EBITDA breakeven. The company has completed 40 product tech transfers at this facility, with another 27 under development.
On the international business front, the company is transitioning from a distributor-led model to holding marketing authorizations directly, which it expects will enhance margins. New product approvals were received in markets including Myanmar, the Philippines, South Africa, Colombia, Germany, and Ecuador. Additionally, the company signed an in-licensing agreement with a Canadian aesthetics company for fillers to complement its botulinum toxin portfolio in India.
Historical Stock Returns for Gufic BioSciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.46% | +5.50% | +12.09% | +13.83% | +9.81% | +112.12% |
How will the transition from a distributor-led model to holding marketing authorizations directly impact international expansion timelines and initial costs?
What specific product mix and geography strategies will drive the projected annual gross margin improvement of 0.50% to 1%?
At what capacity utilisation level does the Indore facility expect to generate significant cash flow contribution?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
